156 related articles for article (PubMed ID: 38577589)
1. NEDD1 overexpression increases cell proliferation, tumor immune escape, and drug resistance in LUAD.
Zhuo T; Wu Z; Chen S; Yang C; Huang H; Gan J; Lyu J; Xiao J; Li Z; Qin S; Wu Y
J Cancer; 2024; 15(9):2460-2474. PubMed ID: 38577589
[No Abstract] [Full Text] [Related]
2. lncRNA CERS6-AS1 upregulates the expression of ANLN by sponging miR-424-5p to promote the progression and drug resistance of lung adenocarcinoma.
Ting Z; Wu Z; Yang C; Li Z; Huang H; Gan J; Li N; Li X; Lyu J; Wu Y; Qin S
Noncoding RNA Res; 2024 Mar; 9(1):221-235. PubMed ID: 38094657
[TBL] [Abstract][Full Text] [Related]
3. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
4. PLK4-phosphorylated NEDD1 facilitates cartwheel assembly and centriole biogenesis initiations.
Chi W; Wang G; Xin G; Jiang Q; Zhang C
J Cell Biol; 2021 Jan; 220(1):. PubMed ID: 33351100
[TBL] [Abstract][Full Text] [Related]
5. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma.
Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S
Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773
[TBL] [Abstract][Full Text] [Related]
6. SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma.
He X; Ma Y; Huang Z; Wang G; Wang W; Zhang R; Guo G; Zhang X; Wen Y; Zhang L
Thorac Cancer; 2023 Aug; 14(23):2275-2287. PubMed ID: 37424293
[TBL] [Abstract][Full Text] [Related]
7. High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation.
Wu Z; Zhuo T; Li Z; Zhu Y; Wu J; Liang G; Dai L; Wang Y; Tan X; Chen M
J Cancer; 2023; 14(12):2301-2314. PubMed ID: 37576392
[No Abstract] [Full Text] [Related]
8. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L
J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025
[TBL] [Abstract][Full Text] [Related]
9.
Zheng X; Han L; Guan J; Chen C; Zhang Y; Zhang J; Zhang Y; Liu S; Su J; Liu M; Huang H
Front Oncol; 2023; 13():1274439. PubMed ID: 38152367
[TBL] [Abstract][Full Text] [Related]
10. LINC01117 inhibits invasion and migration of lung adenocarcinoma through influencing EMT process.
Liu L; Ren W; Du L; Xu K; Zhou Y
PLoS One; 2023; 18(6):e0287926. PubMed ID: 37384755
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis and WDFY4 as novel targets for immunotherapy of lung adenocarcinoma.
Huang L; Zhong L; Cheng R; Chang L; Qin M; Liang H; Liao Z
Aging (Albany NY); 2023 Sep; 15(18):9676-9694. PubMed ID: 37728413
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of Immune Implication and Prognostic Value of
Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
Front Oncol; 2021; 11():798425. PubMed ID: 35047409
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and immune infiltrative biomarkers of CENPO in pan-cancer and its relationship with lung adenocarcinoma cell proliferation and metastasis.
Wang Y; Ye D; Li Y; Lv F; Shen W; Li H; Tian L; Fan Z; Li Y; Wang Y; Li F; Chen Y
BMC Cancer; 2023 Aug; 23(1):735. PubMed ID: 37558987
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis.
Li ZH; Li JY; Wu ZT; Zhu YJ; Zhuo T; Nong JS; Qian J; Peng HJ; Dai L; Wang YY; Chen MW; Zeng XC
J Cell Mol Med; 2024 Mar; 28(6):e18135. PubMed ID: 38429900
[TBL] [Abstract][Full Text] [Related]
16. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
Wei S; Xing J; Lu K; Wang K; Yu W
Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of GNPNAT1 Predicts Poor Prognosis and Correlates With Immune Infiltration in Lung Adenocarcinoma.
Liu W; Jiang K; Wang J; Mei T; Zhao M; Huang D
Front Mol Biosci; 2021; 8():605754. PubMed ID: 33842535
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related miRNA-195-5p Inhibits the Progression of Lung Adenocarcinoma by Targeting Polypyrimidine Tract-Binding Protein 1.
Duan L; Wang J; Zhang D; Yuan Y; Tang L; Zhou Y; Jiang X
Front Oncol; 2022; 12():862564. PubMed ID: 35600383
[TBL] [Abstract][Full Text] [Related]
20. JAM2 is a prognostic biomarker and inhibits proliferation, metastasis and epithelial-mesenchymal transition in lung adenocarcinoma.
Dong Y; Zhang J; Xie S; Di S; Fan B; Gong T
J Gene Med; 2024 Feb; 26(2):e3679. PubMed ID: 38404047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
